Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269741 | 0.80 | CYP3A4 (0.47) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL6220134 | 0.75 | CYP3A4 (0.46) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL6222140 | 0.72 | CYP3A4 (0.44) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL27918615 | 0.72 | CYP3A4 (0.50) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL9863183 | 0.70 | CYP3A4 (0.44) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL29500358 | 0.70 | CYP3A4 (0.58) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL48414 | 0.70 | CYP3A4 (0.58) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31115174 | 0.70 | CYP3A4 (0.52) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31115173 | 0.70 | CYP3A4 (0.52) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL29351907 | 0.70 | CYP3A4 (0.58) | CYP3A4TRPA1ALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431673-B2 | Radiation curable compositions | CYTEC SURFACE SPECIALTIES S.A. (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431673-B2 | Radiation curable compositions | CYTEC SURFACE SPECIALTIES S.A. (BE) | 2013-04-30 | — | — | US | disclosed |
| US-20120059186-A1 | RADIATION CURABLE COMPOSITIONS | ALLNEX BELGIUM S.A. (BE) | 2012-03-08 | — | — | US | disclosed |
| US-20120059186-A1 | RADIATION CURABLE COMPOSITIONS | ALLNEX BELGIUM S.A. (BE) | 2012-03-08 | — | — | US | disclosed |
| US-20110028641-A1 | Radiation Curable Compositions | CYTEC SURFACE SPECIALTIES, S.A. (BE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028641-A1 | Radiation Curable Compositions | CYTEC SURFACE SPECIALTIES, S.A. (BE) | 2011-02-03 | — | — | US | disclosed |
| EP-2267050-A1 | Radiation Curable Compositions | Cytec Surface Specialties, S.A. (BE) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010145891-A1 | RADIATION CURABLE COMPOSITIONS | CYTEC SURFACE SPECIALTIES, S.A. (BE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2009065743-A1 | RADIATION CURABLE COMPOSITIONS | CYTEC SURFACE SPECIALTIES, S.A. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059186-A1 | RADIATION CURABLE COMPOSITIONS | XRCC6, XRCC5, RAD51 | CYP3A4 2898/4885TRPA1 3852/4885ALDH1A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.